SCM
YMAB

Soleus Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Soleus Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-349,982
Closed -$1.58M – 113
2025
Q2 		$1.58M Hold
349,982
– – 0.1% 79
2025
Q1 		$1.55M Hold
349,982
– – 0.11% 66
2024
Q4 		$2.74M Sell
349,982
-50,000
-13% -$609K 0.17% 65
2024
Q3 		$5.26M Sell
399,982
-248,000
-38% -$3.14M 0.41% 60
2024
Q2 		$7.83M Buy
647,982
+77,000
+13% +$1.04M 0.69% 46
2024
Q1 		$9.28M Buy
570,982
+413,800
+263% +$5.58M 0.69% 45
2023
Q4 		$1.07M Hold
157,182
– – 0.12% 60
2023
Q3 		$857K Hold
157,182
– – 0.08% 82
2023
Q2 		$1.07M Buy
157,182
+70,000
+80% +$525K 0.12% 84
2023
Q1 		$437K Hold
87,182
– – 0.05% 76
2022
Q4 		$425K Hold
87,182
– – 0.06% 70
2022
Q3 		$1.26M Sell
87,182
-49,000
-36% -$811K 0.17% 67
2022
Q2 		$2.06M Sell
136,182
-102,800
-43% -$1.2M 0.32% 60
2022
Q1 		$2.84M Sell
238,982
-71,512
-23% -$734K 0.37% 49
2021
Q4 		$5.03M Buy
310,494
+44,794
+17% +$957K 0.5% 38
2021
Q3 		$7.58M Buy
265,700
+121,400
+84% +$3.83M 1.18% 27
2021
Q2 		$4.88M Buy
+144,300
New +$4.63M 0.75% 27

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Soleus Capital Management's YMAB Position: Q3 2025 in Review

Soleus Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 349,982 shares — an estimated $1.58M sold.

Soleus Capital Management first reported a position in YMAB in Q2 2021 and held it in 17 quarters. The position peaked at $9.28M in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Soleus Capital Management reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 349,982 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.58M.
  • Soleus Capital Management first reported a position in Y-mAbs Therapeutics in Q2 2021 and held it in 17 quarters.
  • Soleus Capital Management's Y-mAbs Therapeutics position peaked at $9.28M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.